Here’s what you should know:
1. Oppenheimer revised its predictions from the initial $0.49 per share.
2. In addition, Oppenheimer gave Envision an “outperform” rating and a $40 price target on the stock.
3. Several other analysts published predictions, as well. Robert Baird reissued its “buy” rating, with a price target of $55. Bank of America decreased their target from $72 to $60 while also setting a “buy” rating on the stock.
4. In total, nine companies issued a “buy” rating, eight a “hold” rating and one a “sell” rating. The consensus is a “hold” rating, and a price target of $41.
More articles on transactions/valuations:
Effort to eliminate Mississippi’s CON law for ASCs tabled, but not dead
$10M gift sways Massachusetts hospital to dedicate outpatient center to donors
5 things to know about the trend toward microhospitals in 2018 — what does it mean for ASCs?
